Browse press releases
The newest releases come first, each with its full text here and a link to its original. Try the filters to narrow them down.
- ParaZero Technologies Ltd.ParaZero Signs an MOU with a Tier-1 European Defense Company to Integrate Autonomous Counter-UAS System Across its Armored Vehicle ArsenalMOU followed an initial DefendAir Net Pods order and lay down plans for joint demonstration and on-site ParaZero engineering support for vehicle integration
- Sceye's Stratospheric Platform Re-enters United States After Record-Breaking Roundtrip Stratospheric Flight Between U.S. and JapanThe journey, which lasted 30 days and traversed nearly 30,000 km, included operating for a week in the stratosphere over Japan. While over Japan, Sceye and its partner SoftBank Corp. successfully verified Direct-to-Device connectivity to unmodified devices, HAPS-based communications with...
- RZOLV Technologies Inc.RZOLV Technologies to Present at Peterson Capital Canada Growth Conference in Dublin, IrelandRZOLV Technologies Inc. (TSXV: RZL) (OTCQB: RZOLF) (FSE: S711) ("RZOLV" or the "Company") is pleased to announce that the Company will participate in the Peterson Capital Canada Growth Conference, being held in Dublin, Ireland, from October 1-3, 2026.Duane Nelson, President and CEO of RZOLV Technologies, will present the RZOLV technology platform and the Company's corporate and commercialization strategy to an audience of...
- AE Fuels CorporationAE Fuels Joins US Defense Industrial Base Consortium as It Advances Allied Critical Minerals StrategyAE Fuels Corporation (TSXV: AEF) (OTCQB: NRGFF) ("AEF" or the "Company") is pleased to announce that it has qualified to join the U.S. Defense Industrial Base Consortium ("DIBC"), providing the Company with a platform to engage with U.S. Government, industry and other participants focused on strengthening the U.S. defense industrial base.DIBC membership aligns directly with AEF's strategy to develop secure critical-minerals...
- Adagene Inc. SAN DIEGO andAdagene Achieves Milestone in Collaboration with Exelixis for Advancement of SAFEbody® Antibody-Drug Conjugate CandidatesAdagene Inc. (“Adagene”) (Nasdaq: ADAG), a platform-driven, clinical-stage biotechnology company transforming the discovery and development of novel antibody-based therapies, today announced the achievement of a milestone in its ongoing collaboration and license agreement with Exelixis, Inc. (“Exelixis”).
- ProQR Announces First Participant Dosed in Phase 1 Study of AX-0811 and Virtual Investor and Analyst Educational Event on September 30, 2026LEIDEN, Netherlands & — ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a clinical-stage company dedicated to changing lives through transformative RNA therapies based on its proprietary ADAR-mediated Axiomer™ RNA editing technology platform, today announced that the first participant has been dosed in the Phase 1 clinical trial of AX-0811 in healthy volunteers.
- 2026年，Agent安全正在成为AI落地的“第一命题”文｜产业家 韦斗斗 编辑｜皮爷 当安全本身演变成为了确保Agent持续、自主运行不可或缺的组件时，其产品形态也随之发生了质变。这种从“事后拦截”向“运行时持续护航”的转变，正在彻底打破一次性攻防服务的天花板，真正驱动Agent安全从边缘的项目制零碎支出，迈向企业长期的常态化IT基础设施预算。 2026年的AI安全，正处在一个极为微妙的位置上。 一边是企业对AI智能体放权并深入核心业务的爆发式需求；另一边则是传统安全体系在面对动态、长程决策数字员工的失灵。 今年4月，汽车租赁软件公司PocketOS遭遇了一场颇具代表性的事故。 当时，一名工程师让Cursor里的编码智能体处理测试环境中的一个常规问题。Agent遇到凭据不匹配后，没有停下来等待人工处理，而是自行搜索代码库，找到一个权限范围过大的Railway API Token，随后调用基础设施接口删除存储卷。 整个过程只有9秒。等工程师反应过来，公司的生产数据库以及同一存储卷上的
- Toronto Stock Exchange Announces the 2026 TSX30, Recognizing the Companies Scaling into Global LeadersToronto, Ontario--(ACN Newswire - September 9, 2026) - Toronto Stock Exchange (TSX) today announced the 2026 TSX30®, an annual ranking of the 30 top-performing companies based on three-year dividend-adjusted share price performance. The 2026 list delivered the strongest average returns since the program launched in 2019, with 785% average dividend-adjusted share price appreciation over three years-nearly double the 431% achieved by the 2025 TSX30. Collectively, the 2026 TSX30 companies represent $252.6 billion in total market capitalization, having added $225.7 billion in market value over three years. Topping the list for the second consecutive year is Celestica Inc. (TSX: CLS), a technology company providing critical data centre infrastructure for AI, cloud, and hybrid cloud products and services, with a 2,590% dividend-adjusted share price increase over three years. Over the same period, Celestica's market capitalization increased from $1.9 billion to $59.5 billion (as at June 30, 2026), demonstrating how rapidly a Canadian company can scale into a major global market player. Celestica also joined the S&P/TSX 60 Index* during the three-year period covered by this year's TSX30. Beyond the record returns, this year's TSX30 tells a broader story of company-building in Canada, exemplifying how high-growth companies can successfully scale into larger, globally competitive companies. Four distinct sectors are represented among the top five companies, reflecting the diversity of Canada's public markets and the emergence of companies competing in important areas of the global economy, from critical minerals and advanced technology to energy and industrial capacity. "Just as nation-building is a priority for Canada, company-building must also be a national priority," said Loui Anastasopoulos, CEO, Toronto Stock Exchange. "The 2026 TSX30 demonstrates the potential of Canadian companies to grow, scale and compete with the best in the world. Half of this year's top performers are graduates of TSX Venture Exchange, a powerful example of how Canada's capital markets can help build the next generation of Canadian champions and support them as they grow into globally competitive companies." "Being recognized at the top of the TSX30 for a second consecutive year reflects the strength of our strategy, our team's execution and the trust our customers place in Celestica," said Rob Mionis, Chair and Chief Executive Officer, Celestica. "We continue to scale our business by enabling critical AI data center infrastructure and advancing technologies in high-growth markets. This recognition is a testament to our people, our capabilities and our continued focus on delivering value for our customers and shareholders." TSXV-to-TSX pipeline helps build the next generation of global leaders This year's results demonstrate the strength of Canada's distinctive two-tiered public market ecosystem. Half of the companies on the 2026 TSX30 are graduates of TSX Venture Exchange (TSXV), the highest number of TSXV graduates featured in a TSX30 ranking since the program's inception. The 15 graduates span mining, energy, technology and industrial sectors, including 11 of the 18 mining companies and both oil & gas companies on the list. Mining representation broadens across precious metals and critical minerals Mining companies account for 60% of the 2026 TSX30-18 of 30 companies-the highest number of mining companies in a TSX30 ranking, and up from 57% last year. Gold companies remain strongly represented amid continued economic and geopolitical uncertainty, with Montage Gold Corp. (TSX: MAU) ranking second in the 2026 ranking with a 2,502% three-year dividend-adjusted share price appreciation. Beyond gold, this year's mining cohort is also more diversified than in 2025, with four companies focused on silver, three on copper and one on rare earths, underscoring the sector's depth and Canada's role in securing strategic supply chains. Critical mineral developers include Faraday Copper Corp. (TSX: FDY, +688%), Perpetua Resources Corp. (TSX: PPTA, +507%), Aclara Resources Inc. (TSX: ARA, +587%), and Trilogy Metals Inc. (TSX: TMQ, +570%). Technology companies represented across AI, space, aerospace and digital infrastructure Five technology companies are represented on the 2026 TSX30. Together, they added $85.3 billion in market capitalization over three years, the second-largest contribution of any sector featured in the 2026 ranking. These companies delivered an average three-year dividend-adjusted share price return of 981%. Alongside Celestica, the featured technology companies highlight how TSX-listed companies across space, aerospace, defence and digital infrastructure can grow. MDA Space Ltd. (TSX: MDA) delivered a 617% return, alongside Hut 8 Corp. (TSX: HUT, +645%), Firan Technology Group Corporation (TSX: FTG, +577%) and Telesat Corporation (TSX: TSAT, +475%). International energy growth and infrastructure investment drive returns Oil & Gas returns to the TSX30 in 2026, representing two of the 30 companies after being absent from last year's ranking. Tenaz Energy Corp. (TSX: TNZ, +1,463%) and Valeura Energy Inc. (TSX: VLE, +471%) added a combined $2.3 billion in market value over three years. Both have pursued growth through international assets, reflecting how Canadian-listed energy companies have the potential to increase their global footprint. Industrial companies also delivered strong performance amid increased investment in essential infrastructure and grid electrification. Hammond Power Solutions Inc. (TSX: HPS.A, +625%), Bird Construction Inc. (TSX: BDT, +738%) and CES Energy Solutions Corp. (TSX: CEU, +570%) together added $8.7 billion in market capitalization over three years. Elsewhere on the ranking, specialty materials producer 5N Plus Inc. (TSX: VNP, +1,243%) returned to the top five this year, while senior housing operator Extendicare Inc. (TSX: EXE, +466%) marked the Real Estate sector's first return to the TSX30 since 2019. Additional highlights from the 2026 ranking: Domestic roots with global reach: 26 of the 30 ranked firms (87%) are headquartered in Canada, with Ontario (15) and British Columbia (7) together accounting for 73% of the list. Scaling into major market indices: 14 TSX30 companies joined the S&P/TSX Composite Index during the three-year period covered by this year's ranking. Two-thirds of TSX30 companies are included in either the S&P/TSX Composite Index* or S&P/TSX 60 Index, reflecting the scale achieved by many of this year's top performers. Sustained performance: Half of the companies on the 2026 TSX30 are returning honourees, including six multi-year honourees: Celestica Inc. (TSX: CLS), Bird Construction Inc. (TSX: BDT), Hammond Power Solutions Inc. (TSX: HPS.A,), Lundin Gold Inc. (TSX: LUG), Trilogy Metals Inc. (TSX: TMQ) and DPM Metals Inc. (TSX: DPM). For detailed results and further information about the ranking methodology, visit tsx.com/tsx30. The 2026 TSX30 ranking RankingCompany NameTickerThree-Year Dividend-Adjusted Share Price Performance 1Celestica Inc.CLS2590% 2Montage Gold Corp.MAU2502% 3Tenaz Energy Corp.TNZ1463% 45N Plus Inc.VNP1243% 5Avino Silver & Gold Mines Ltd.ASM958% 6Discovery Mining Ltd.DSV934% 7AbraSilver Resource Corp.ABRA904% 8G Mining Ventures Corp.GMIN853% 9Bird Construction Inc.BDT738% 10Faraday Copper Corp.FDY688% 11Andean Precious Metals Corp.APM666% 12Hut 8 Corp.HUT645% 13Hammond Power Solutions Inc.HPS.A625% 14MDA Space Ltd.MDA617% 15Aclara Resources Inc.ARA587% 16Firan Technology Group CorporationFTG577% 17Trilogy Metals Inc.TMQ570% 18CES Energy Solutions Corp.CEU570% 19Aris Mining CorporationARIS563% 20IAMGold CorporationIMG541% 21Perpetua Resources Corp.PPTA507% 22Skeena Resources LimitedSKE492% 23Lundin Gold Inc.LUG484% 24Americas Gold and Silver CorporationUSA477% 25Telesat CorporationTSAT475% 26Valeura Energy Inc.VLE471% 27Extendicare Inc.EXE466% 28Kinross Gold CorporationK452% 29DPM Metals Inc.DPM449% 30Hudbay Minerals Inc.HBM430% Source: All data is sourced from TSX/TSXV Market Intelligence Group analysis. Based on historical dividend-adjusted share prices from S&P Capital IQ as at June 30, 2026. *The S&P/TSX Composite Index and the S&P/TSX 60 Index (the "Indices") are the products of S&P Dow Jones Indices LLC ("SPDJI") and TSX Inc. ("TSX"). S&P® is a registered trademark of S&P Global, Inc. or its affiliates ("S&P"); Dow Jones® is a registered trademark of Dow Jones Trademark Holdings LLC ("Dow Jones"); and TSX® is a registered trademark of TSX. These trademarks have been sublicensed for certain purposes by SPDJI and TSX. SPDJI, Dow Jones, S&P and TSX do not sponsor, endorse, sell or promote any products based on the Indices and none of such parties make any representation regarding the advisability of investing in such product(s) nor do they have any liability for any errors, omissions or interruptions of the Indices or any data related thereto. About TMX Group (TSX:X) TMX Group operates global markets, and builds digital communities and analytic solutions that facilitate the funding, growth and success of businesses, traders and investors. TMX Group's key operations include Toronto Stock Exchange, TSX Venture Exchange, TSX Alpha Exchange, TMX Australia Exchange, The Canadian Depository for Securities, Montréal Exchange, Canadian Derivatives Clearing Corporation, TSX Trust, TMX Trayport, TMX Datalinx, TMX VettaFi and TMX Newsfile, which provide listing markets, trading markets, clearing facilities, depository services, technology solutions, data products and other services to the global financial community. TMX Group is headquartered in Toronto and operates offices across North America (Montréal, Calgary, Vancouver and New York), as well as in key international markets including London, Singapore, Vienna and Sydney. For more information about TMX Group, visit www.tmx.com. Follow TMX Group on X: @TMXGroup. For more information on the 2026 TSX30, please contact: Jordan Heath-Rawlings Earned Media Director Hill & Knowlton 647-225-2735 [email protected] For more information on TMX Group, please contact: Mathieu Labrèche Director, Corporate Communications and Public Affairs TMX Group 416-206-3132 [email protected] Copyright © 2026 TSX Inc. All rights reserved. Do not copy, distribute, sell or modify this press release without TSX Inc.'s prior written consent. This information is provided for information purposes only. Neither TMX Group Limited nor any of its affiliated companies guarantees the completeness of the information contained in this press release, and we are not responsible for any errors or omissions in or your use of, or reliance on, the information. This press release is not intended to provide legal, accounting, tax, investment, financial or other advice and should not be relied upon for such advice. The information provided is not an invitation to purchase securities listed on Toronto Stock Exchange and/or TSX Venture Exchange. TMX Group and its affiliated companies do not endorse or recommend any securities referenced in this press release. TMX, the TMX design, TMX Group, Toronto Stock Exchange, TSX, TSX30, the TSX30 design, TSX Venture Exchange, and TSXV are the trademarks of TSX Inc.
- CMS: Initial Prescriptions for Silevimig Injection, the World's First Bispecific Antibody Against Rabies, Issued in ChinaSHENZHEN, Sept 9, 2026 - On 9 September, China Medical System Holdings Limited (867.HK/8A8.SG) (“CMS” or the “Group”) is pleased to announce that the initial prescriptions for the Class 1 innovative drug Silevimig Injection (the “Product”) have recently been issued in multiple hospitals across China, including Beijing Luhe Hospital of Capital Medical University, Wenzhou People’s Hospital, Kaiping Central Hospital, Dongguan Guangji Hospital and Huidong Jilong Ankang Hospital. This marks that the world’s first bispecific antibody for passive immunization against rabies has officially commenced its large-scale clinical application, offering a better solution for urgent post-exposure management against rabies in China. Dual-Epitope Neutralization with Low Dosing, Addressing Clinical Pain Points Silevimig Injection is the world’s first fully human bispecific antibody targeting dual epitopes (G protein epitopes I and III) of the rabies virus, which is consistent with the World Health Organization (“WHO”) recommendation for a “cocktail” therapeutic paradigm. It can effectively neutralize different viral strains or genotypes of the rabies virus, providing immediate protection before the establishment of full protection by active rabies vaccination, and building a critical line of defense against viral infection. The Product is currently the passive immunization product with the smallest dose for rabies (0.05 mg/kg); compared with human rabies immune globulin (“HRIG”), it requires less injection volume and easier administration, which can effectively reduce pain and improve compliance for patient. Manufactured using recombinant technology, the Product is non-plasma-derived and carries no risk of blood-borne infections. It can be manufactured at scale through standardized and stable processes, with controllable production costs, while offering a single active ingredient, consistent quality and minimal batch-to-batch variability. These advantages open up new possibilities for improving the safety, standardized supply and patient accessibility of rabies passive immunization products, with the potential to further increase market penetration. Initial Prescriptions Issued Within About Two Months After Approval, Academic-Driven Commercialization Platform Accelerating Value Realization Silevimig Injection was approved for marketing in China in June 2026. Following the approval, CMS worked closely with its partner Genrix Bio to advance critical workstreams including drug supply, market access and academic promotion, while integrating expert networks and market resources. The inital prescriptions were issued in China within approximately two months, accelerating the translation of innovation outcomes into a clinically accessible new treatment option. Currently, CMS has nine commercialized innovative drugs that are progressively achieving large-scale clinical application across China, accelerating the realization of the clinical value of each quality medicine. Going forward, CMS will remain focused on clinical unmet needs and continue to build a differentiated innovative product portfolio through a dual-track system of in-house R&D and collaborative R&D, accelerating accessibility of quality innovative drugs and taking concrete action to safeguard patients’ lives and health. About Rabies Rabies is an acute zoonotic disease caused by RABV, clinically characterized by aerophobia, hydrophobia, pharyngeal muscle spasms and progressive paralysis[1], with a case-fatality rate approaching 100%. At present, there is no proven treatment for rabies once clinical symptoms appear. Standardized post-exposure management, comprising wound care, vaccination and passive immunization administered as needed, remains the most effective strategy[2]. As vaccine-induced antibodies require 1-2 weeks after the first dose of vaccine injection to reach protective levels, passive immunization provides immediate coverage [1]. According to the National Technical Guidelines for the Rabies Exposure Prophylaxis (2023 Edition), patients with Category III exposure, patients with confirmed Category II exposure involving severe immunodeficiency, and patients with Category II exposure involving wounds to the head or face while the health status of the offending animal cannot be determined should receive passive immunization at the same time as the first dose of rabies vaccine[3]. In China, more than 40 million people are exposed to rabies annually, of whom approximately 40% fall under Category III exposure[1]. However, due to factors such as limited awareness, high price, and restricted accessibility, only about 15% of Category III cases receive passive immunization[1]. Currently, the primary passive immunization option in China is HRIG. However, HRIG must be sourced from healthy donors, making it difficult and costly to obtain. Furthermore, it carries potential risks of blood-borne infections. This has led to a low penetration rate of passive immunization products in China. More Information about Silevimig Injection In a Phase III clinical trial in adults in China, Silevimig Injection met its primary efficacy endpoint, demonstrating non-inferior protective efficacy compared with HRIG, the currently most used passive immunization product in China. The Product provides immediate protection during the early stages of rabies virus exposure without compromising the active immune response induced by vaccination. In addition, a Phase III clinical trial in children and adolescents aged 2 to <18 years is currently ongoing in China. The Product has been granted a patent in China. In September 2025, the Group through subsidiaries of the Company entered into an Exclusive Collaboration Agreement (the “Agreement”) with Chongqing Genrix Biopharmaceutical Co., Ltd. In accordance with the Agreement, the Group has obtained exclusive commercialization rights for the Product in mainland China and exclusive licensing rights for the rest of the Asia-Pacific region, the Middle East and North Africa. The collaboration term extends until ten years after the Product receives the marketing approval in Mainland China (the “Initial Term for the Product”). Unless terminated or dissolved under the terms set forth in the Agreement, the Agreement will automatically renew for successive ten-year periods upon expiration of the Initial Term for the Product. About CMS CMS is an innovative pharmaceutical company focused on the identification, building, and full lifecycle management of differentiated specialty pharmaceuticals. With a dual-engine approach of in-house R&D and collaborative R&D, and leveraging its core capability to build markets and brands from the ground up, the Group enables each medicine to fully realize both its clinical value and commercial value. CMS has established an end-to-end capability loop across the full product lifecycle—precisely identifying quality innovation targets, matching them with optimal development pathways, and efficiently advancing clinical development and registration; developing medical strategies aligned with clinical needs, and driving scaled clinical adoption through a professional academic promotion system and network. CMS focuses on advantaged specialties including cardiovascular-kidney-metabolic, central nervous system, gastroenterology, ophthalmology, and skin health. Through professional academic promotion and academic resources across multiple disease areas, CMS has built sustainable scale advantages in specialties, with its skin health business becoming a leading player in its segment. Meanwhile, CMS continues to strengthen its international replication capabilities, validating the transferability of its business model in emerging markets such as Southeast Asia and the Middle East, and injecting long-term momentum for the Group’s high-quality, sustainable development. Reference: 1. Chinese Center for Disease Control and Prevention. Technical Guidelines for Human Rabies Prevention and Control (2016). https://www.chinacdc.cn/jkyj/crb2/yl/kqb/jswj_kqb/202409/P020240906525420231910.pdf 2. Yin Wenwu, Wang Chuanlin, et al. Expert consensus on rabies exposure prophylaxis [J]. Chinese Journal of Preventive Medicine, 2019, 53(7): 668–679. DOI: 10.3760/cma.j.issn.0253-9624.2019.07.004 3. Chinese Center for Disease Control and Prevention. National Technical Guidelines for the Rabies Exposure Prophylaxis (2023 Edition). https://www.chinacdc.cn/jkyj/crb2/yl/kqb/jswj_kqb/202409/P020240906525421817465.pdf CMS Disclaimer and Forward-Looking Statements This press release is not intended to promote any products to you and is not for advertising purposes. This press release does not recommend any drugs, medical devices and/or indications. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert. This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever. This press release has been prepared by CMS based on information and data which it considers reliable, but CMS makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on the truth, accuracy, completeness, fairness and reasonableness of the contents of this press release. Certain matters discussed in this press release may contain statements regarding the Group’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. Any forward-looking statements and projections made by third parties included in this press release are not adopted by the Group and the Company is not responsible for such third-party statements and projections. Media ContactBrand: China Medical System Holdings Ltd.Contact: CMS Investor RelationsEmail: [email protected]: https://web.cms.net.cn/en/home/
- CMS: Initial Prescriptions for Silevimig Injection, the World's First Bispecific Antibody Against Rabies, Issued in ChinaSHENZHEN, Sept 9, 2026 - On 9 September, China Medical System Holdings Limited (867.HK/8A8.SG) (“CMS” or the “Group”) is pleased to announce that the initial prescriptions for the Class 1 innovative drug Silevimig Injection (the “Product”) have recently been issued in multiple hospitals across China, including Beijing Luhe Hospital of Capital Medical University, Wenzhou People’s Hospital, Kaiping Central Hospital, Dongguan Guangji Hospital and Huidong Jilong Ankang Hospital. This marks that the world’s first bispecific antibody for passive immunization against rabies has officially commenced its large-scale clinical application, offering a better solution for urgent post-exposure management against rabies in China. Dual-Epitope Neutralization with Low Dosing, Addressing Clinical Pain Points Silevimig Injection is the world’s first fully human bispecific antibody targeting dual epitopes (G protein epitopes I and III) of the rabies virus, which is consistent with the World Health Organization (“WHO”) recommendation for a “cocktail” therapeutic paradigm. It can effectively neutralize different viral strains or genotypes of the rabies virus, providing immediate protection before the establishment of full protection by active rabies vaccination, and building a critical line of defense against viral infection. The Product is currently the passive immunization product with the smallest dose for rabies (0.05 mg/kg); compared with human rabies immune globulin (“HRIG”), it requires less injection volume and easier administration, which can effectively reduce pain and improve compliance for patient. Manufactured using recombinant technology, the Product is non-plasma-derived and carries no risk of blood-borne infections. It can be manufactured at scale through standardized and stable processes, with controllable production costs, while offering a single active ingredient, consistent quality and minimal batch-to-batch variability. These advantages open up new possibilities for improving the safety, standardized supply and patient accessibility of rabies passive immunization products, with the potential to further increase market penetration. Initial Prescriptions Issued Within About Two Months After Approval, Academic-Driven Commercialization Platform Accelerating Value Realization Silevimig Injection was approved for marketing in China in June 2026. Following the approval, CMS worked closely with its partner Genrix Bio to advance critical workstreams including drug supply, market access and academic promotion, while integrating expert networks and market resources. The inital prescriptions were issued in China within approximately two months, accelerating the translation of innovation outcomes into a clinically accessible new treatment option. Currently, CMS has nine commercialized innovative drugs that are progressively achieving large-scale clinical application across China, accelerating the realization of the clinical value of each quality medicine. Going forward, CMS will remain focused on clinical unmet needs and continue to build a differentiated innovative product portfolio through a dual-track system of in-house R&D and collaborative R&D, accelerating accessibility of quality innovative drugs and taking concrete action to safeguard patients’ lives and health. About Rabies Rabies is an acute zoonotic disease caused by RABV, clinically characterized by aerophobia, hydrophobia, pharyngeal muscle spasms and progressive paralysis[1], with a case-fatality rate approaching 100%. At present, there is no proven treatment for rabies once clinical symptoms appear. Standardized post-exposure management, comprising wound care, vaccination and passive immunization administered as needed, remains the most effective strategy[2]. As vaccine-induced antibodies require 1-2 weeks after the first dose of vaccine injection to reach protective levels, passive immunization provides immediate coverage [1]. According to the National Technical Guidelines for the Rabies Exposure Prophylaxis (2023 Edition), patients with Category III exposure, patients with confirmed Category II exposure involving severe immunodeficiency, and patients with Category II exposure involving wounds to the head or face while the health status of the offending animal cannot be determined should receive passive immunization at the same time as the first dose of rabies vaccine[3]. In China, more than 40 million people are exposed to rabies annually, of whom approximately 40% fall under Category III exposure[1]. However, due to factors such as limited awareness, high price, and restricted accessibility, only about 15% of Category III cases receive passive immunization[1]. Currently, the primary passive immunization option in China is HRIG. However, HRIG must be sourced from healthy donors, making it difficult and costly to obtain. Furthermore, it carries potential risks of blood-borne infections. This has led to a low penetration rate of passive immunization products in China. More Information about Silevimig Injection In a Phase III clinical trial in adults in China, Silevimig Injection met its primary efficacy endpoint, demonstrating non-inferior protective efficacy compared with HRIG, the currently most used passive immunization product in China. The Product provides immediate protection during the early stages of rabies virus exposure without compromising the active immune response induced by vaccination. In addition, a Phase III clinical trial in children and adolescents aged 2 to <18 years is currently ongoing in China. The Product has been granted a patent in China. In September 2025, the Group through subsidiaries of the Company entered into an Exclusive Collaboration Agreement (the “Agreement”) with Chongqing Genrix Biopharmaceutical Co., Ltd. In accordance with the Agreement, the Group has obtained exclusive commercialization rights for the Product in mainland China and exclusive licensing rights for the rest of the Asia-Pacific region, the Middle East and North Africa. The collaboration term extends until ten years after the Product receives the marketing approval in Mainland China (the “Initial Term for the Product”). Unless terminated or dissolved under the terms set forth in the Agreement, the Agreement will automatically renew for successive ten-year periods upon expiration of the Initial Term for the Product. About CMS CMS is an innovative pharmaceutical company focused on the identification, building, and full lifecycle management of differentiated specialty pharmaceuticals. With a dual-engine approach of in-house R&D and collaborative R&D, and leveraging its core capability to build markets and brands from the ground up, the Group enables each medicine to fully realize both its clinical value and commercial value. CMS has established an end-to-end capability loop across the full product lifecycle—precisely identifying quality innovation targets, matching them with optimal development pathways, and efficiently advancing clinical development and registration; developing medical strategies aligned with clinical needs, and driving scaled clinical adoption through a professional academic promotion system and network. CMS focuses on advantaged specialties including cardiovascular-kidney-metabolic, central nervous system, gastroenterology, ophthalmology, and skin health. Through professional academic promotion and academic resources across multiple disease areas, CMS has built sustainable scale advantages in specialties, with its skin health business becoming a leading player in its segment. Meanwhile, CMS continues to strengthen its international replication capabilities, validating the transferability of its business model in emerging markets such as Southeast Asia and the Middle East, and injecting long-term momentum for the Group’s high-quality, sustainable development. Reference: 1. Chinese Center for Disease Control and Prevention. Technical Guidelines for Human Rabies Prevention and Control (2016). https://www.chinacdc.cn/jkyj/crb2/yl/kqb/jswj_kqb/202409/P020240906525420231910.pdf 2. Yin Wenwu, Wang Chuanlin, et al. Expert consensus on rabies exposure prophylaxis [J]. Chinese Journal of Preventive Medicine, 2019, 53(7): 668–679. DOI: 10.3760/cma.j.issn.0253-9624.2019.07.004 3. Chinese Center for Disease Control and Prevention. National Technical Guidelines for the Rabies Exposure Prophylaxis (2023 Edition). https://www.chinacdc.cn/jkyj/crb2/yl/kqb/jswj_kqb/202409/P020240906525421817465.pdf CMS Disclaimer and Forward-Looking Statements This press release is not intended to promote any products to you and is not for advertising purposes. This press release does not recommend any drugs, medical devices and/or indications. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert. This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever. This press release has been prepared by CMS based on information and data which it considers reliable, but CMS makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on the truth, accuracy, completeness, fairness and reasonableness of the contents of this press release. Certain matters discussed in this press release may contain statements regarding the Group’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. Any forward-looking statements and projections made by third parties included in this press release are not adopted by the Group and the Company is not responsible for such third-party statements and projections. Media Contact Brand: China Medical System Holdings Ltd. Contact: CMS Investor Relations Email: [email protected] Website: https://web.cms.net.cn/en/home/
- ReviztoRevizto Academy celebrates two years with more than 13,500 certifications awardedAs construction's skills needs evolve, Revizto Academy is helping connect practical digital learning with the realities of modern project delivery. — Revizto, the leading collaboration platform for the architecture, engineering,...
- Rokid Launches AIUI Studio Globally at IFA Berlin 2026, Making AI Glasses Creation More Accessible for EveryoneRokid, a global pioneer in AI-powered smart eyewear and human-computer interaction, announced the global launch of AIUI Studio, an all-in-one agentic AI development platform for Rokid's AI glasses, at IFA Berlin 2026. Rokid AIUI Studio: the spatial AI...